Skip to main content
OpenTrials
Completed

NCT Number: NCT02555280

Coflex PS3 Actual Conditions for Use Study

A 2 and 5 year evaluation of clinical outcomes in the treatment of degenerative spinal stenosis with concomitant low back pain by decompression with additional stabilization using the coflex® Interlaminar Technology for FDA Actual Conditions of Use Study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Desert Institute for Spine Care (DISC), Phoenix, Arizona, United States

Loading trial locations.

About this study

A prospective, multi center, concurrently enrolled, propensity score controlled through Month 60. The purpose is to fully characterize safety and efficacy then the coflex device is used in the intended subject population under actual conditions of use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Radiographic confirmation of at least moderate lumbar stenosis at one or two contiguous levels from L1-L5 that require surgical decompression.
  • Visual Analog Scale back pain score of at least 50 mm on a 100 mm scale.
  • Neurogenic claudication as defined by leg/buttocks or groin pain that can be relieved by flexion such as sitting in a chair.
  • Subject has undergone at least one lumbar injection at any prior time point, AND/OR at least 6 months of prior conservative care without adequate and sustained symptom relief.
  • Skeletally mature
  • Oswestry Low Back Pain Disability Questionnaire score of at least 20/50 (40%).
  • Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
  • Personally signed and dated informed consent document prior to any study-related procedures indicating that the patient has been informed of all pertinent aspects of the trial.

Exclusion criteria

  • Prior fusion or decompressive laminectomy at index lumbar level.
  • Radiographically compromised vertebral bodies at any lumbar level(s) caused by current or past trauma or tumor (e.g., compression fracture).
  • Severe facet hypertrophy that requires extensive bone removal which would cause instability.
  • Isthmic spondylolisthesis or spondylolysis (pars fracture).
  • Degenerative lumbar scoliosis (Cobb angle of greater than 25°).
  • Osteoporsis or is at increased risk of osteoporosis.
  • Back or leg pain of unknown etiology.
  • Axial back pain only, with no leg, buttock, or groin pain.
  • Morbid obesity defined as a body mass index > 40.
  • Known allergy to titanium, titanium alloys, or MR contrast agents.
  • Active or chronic infection - systemic or local.
  • Cauda equina syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction.

Treatment and study plan

coflex® Interlaminar Technology

Device

Decompression plus coflex® Interlaminar Technology

Other names: coflex

Decompression

Procedure

Decompression alone

Primary outcomes

  1. coflex performance compared to IDE

    Time frame: 24and 60 Months

    Evaluation of coflex device performance in conjunction with surgical decompression in an actual conditions of use study.

  2. coflex performance compared to decompression alone from ESCADA study.

    Time frame: 24 Months

    To compare clinical status of patients implanted with the coflex device in conjunction with surgical decompression relative to surgical decompression alone from ESCADA study.

  3. Composite Clinical Success (CCS)

    Time frame: 24 Month

    • No secondary surgical interventions
    • No lumbar epidural injection, nerve block procedures at index level to treat spinal stenosis at any lumbar level
    • 15 point improvement in ODI in subjects with no interventions or injections
    • No new or increasing sensor or motor deficit
    • No major device related adverse events

Secondary outcomes

  1. Change in Oswestry Disability Index (ODI)

    Time frame: Baseline, 24 and 60 months

    Quality of life as determined by ODI. In terms of achieving at least a 15 point improvement.

  2. Change in Visual Analog Scale (VAS) for low back pain

    Time frame: Baseline, 24 and 60 Months

    Low back pain reduction evaluated by use of VAS for back pain. In terms of achieving at least a 20 point improvement.

  3. Change in Visual Analog Scale (VAS) for leg pain

    Time frame: Baseline, 24 and 60 Months

    Leg pain reduction evaluated by use of VAS for leg pain. In terms of achieving at least a 20 point improvement.

  4. Neurological Status

    Time frame: Baseline, 6 weeks, 12, 24, 36, 48, 60 Months

    Assessment of maintenance of improvement after surgery.

  5. Radiographic Assessments

    Time frame: 6 weeks, 12, 24, 60 Months

    • Significant migration or complete expulsion of implant
    • Spinous process fracture
    • Maintenance of foraminal height
    • adjacent level disease
  6. Modified CCS

    Time frame: 24 Month

    CCS will be modified to include no use of a narcotic (opioids or opiates).

  7. Medication Usage

    Time frame: 24 Month

    No use of narcotic (opioids and/or opiates)

Other outcomes

  1. Safety Evaluation

    Time frame: Procedure, 6 week, 12, 24, 36, 48, 60 Months

    Safety will be evaluated by assessing the incidence of device and/or procedure related adverse events, revision, additional stabilizations

Sponsors and collaborators

Lead sponsor

Companion Spine, LLC

Other

Collaborators

  • MCRA

Registry information

Official study title

A 2 and 5 Year Evaluation of Clinical Outcomes in the Treatment of Degenerative Spinal Stenosis With Concomitant Low Back Pain by Decompression With Additional Stabilization Using the Coflex® Interlaminar Technology for FDA Actual Conditions for Use Study.

Acronym: PAS003

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Sep 21, 2015
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.